作者: Janusz W. Rak , Brenda Coomber , Joanne L. Yu
DOI: 10.1007/978-1-59745-035-5_4
关键词:
摘要: Development of therapeutic resistance is intrinsic to the neoplasia and associated with complexity, plasticity, dynamics process. Some aspects drug resistance, such as ability repopulate tumor mass by clonogenic/stem cell subsets or adhesion/aggregation-dependent changes in responsiveness therapy may be related genetic progression, instability, expression oncogenic proteins. Combinations cytoreductive agents oncogene-directed signal transduction inhibitors angiogenic have already produced promising preclinical clinical results. In not-too-distant future, refinement commercialization pharmacogenomic tests cancer will enable more-accurate predictions regarding individual patients new established agents. These data also understanding pathways ways overcome it.